Eiger BioPharmaceuticals Inc. (EIGR) Soars 1.71% on January 22

Equities Staff  |

Eiger BioPharmaceuticals Inc. (EIGR) had a good day on the market for Friday January 22 as shares jumped 1.71% to close at $10.73. About 194,953 shares traded hands on 1,744 trades for the day, compared with an average daily volume of n/a shares out of a total float of 32.53 million. After opening the trading day at $10.46, shares of Eiger BioPharmaceuticals Inc. stayed within a range of $10.79 to $10.43.

With today's gains, Eiger BioPharmaceuticals Inc. now has a market cap of $349.07 million. Shares of Eiger BioPharmaceuticals Inc. have been trading within a range of $14.79 and $4.56 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Eiger BioPharmaceuticals Inc is a late-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Eiger BioPharmaceuticals Inc. is based out of Palo Alto, CA and has some 29 employees. Its CEO is David Cory.

For a complete fundamental analysis of Eiger BioPharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for EIGR.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Eiger BioPharmaceuticals Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Eiger BioPharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: EIGR’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change